October 18, 2021

Both ranibizumab and aflibercept are used as anti-VEGF agents to treat wet AMD. This cross-sectional study, published in Graefe’s Archive for Clinical and Experimental Ophthalmology, evaluated wet AMD outcomes after 12 months in patients who switched from ranibizumab to aflibercept, regardless of previous drug response.  The researchers tested visual acuity, treatment frequency, and retinal morphology after...